The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial.

[1]  P. Barragan,et al.  Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. , 2008, Journal of the American College of Cardiology.

[2]  J. Tardif,et al.  Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. , 2008, Journal of the American College of Cardiology.

[3]  K. Winters,et al.  The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration , 2008, Thrombosis and Haemostasis.

[4]  E. Antman,et al.  Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial , 2007, Circulation.

[5]  S. Iturria,et al.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.

[6]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[7]  C. Macaya,et al.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.

[8]  D. Angiolillo,et al.  Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study , 2007, Circulation.

[9]  J. T. ten Berg,et al.  A head‐to‐head comparison between the VerifyNow® P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention , 2006, Journal of thrombosis and haemostasis : JTH.

[10]  A. Kastrati,et al.  Impact of P‐glycoprotein on clopidogrel absorption , 2006, Clinical pharmacology and therapeutics.

[11]  G. Montalescot,et al.  A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. , 2006, Journal of the American College of Cardiology.

[12]  G. Wong,et al.  Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. , 2006, The American journal of cardiology.

[13]  A. Kastrati,et al.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.

[14]  J. Gorski,et al.  The effect of short‐ and long‐term administration of verapamil on the disposition of cytochrome P450 3A and P‐glycoprotein substrates , 2006, Clinical pharmacology and therapeutics.

[15]  J. Granada,et al.  CLINICAL RESEARCH Interventional Cardiology Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention The Role of Dual Drug Resistance , 2006 .

[16]  A. Kastrati,et al.  Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial , 2005, Circulation.

[17]  V. Pasceri,et al.  Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study* , 2005, Circulation.

[18]  Deepak L. Bhatt,et al.  Variability in platelet responsiveness to clopidogrel among 544 individuals. , 2005, Journal of the American College of Cardiology.

[19]  S. Steinhubl,et al.  Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. , 2004, Journal of the American College of Cardiology.

[20]  R. Wilcox,et al.  Clopidogrel resistance , 2004, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[21]  A. Kastrati,et al.  Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy , 2004, Circulation.

[22]  S. Steinhubl,et al.  Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial , 2003, Circulation.

[23]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[24]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[25]  M. Maftouh,et al.  Structure and stereochemistry of the active metabolite of clopidogrel. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[26]  J. Herbert,et al.  Identification and Biological Activity of the Active Metabolite of Clopidogrel , 2000, Thrombosis and Haemostasis.

[27]  K. Winters,et al.  A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. , 2007, American heart journal.

[28]  P. Tricoci,et al.  “Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study” , 2005 .

[29]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .